Drug Sponsors

Juno Therapeutics acquires Stage Cell Therapeutics

Wednesday, May 13, 2015 12:11 PM

Juno Therapeutics, a Seattle, Wash.-based biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, has acquired Stage Cell Therapeutics, a privately held biotechnology company based in Munich and Göttingen, Germany.

More... »


Moderna launches venture company Elpidera for rare diseases

Wednesday, May 13, 2015 11:57 AM

Moderna Therapeutics, a Cambridge, Mass.-based developer of messenger RNA (mRNA) Therapeutics, has launched Elpidera, a new Moderna venture focused exclusively on the advancement of mRNA-based medicines for the treatment of rare diseases.

More... »


Perrigo acquires Patheon's Mexican operations for $34 million in cash

Wednesday, May 13, 2015 11:54 AM

Perrigo, a consumer goods and pharmaceutical company headquartered in Ireland, has acquired the Mexican operations of Durham, N.C.-based Patheon for $34 million in cash.  The acquisition is expected to be immediately accretive to calendar 2015 adjusted EPS after the exclusion of estimates for intangible amortization and transaction-related costs.

More... »

Baxter BioScience acquires Oncaspar portfolio for leukemia

Wednesday, May 13, 2015 11:51 AM

Baxter International has signed a definitive agreement to acquire the Oncaspar (pegaspargase) product portfolio from Sigma-Tau Finanziaria. Baxter gains the marketed biologic treatment Oncaspar, the investigational biologic calaspargase pegol and an established oncology infrastructure with clinical and sales resources.

More... »

Alexion Pharmaceuticals expands in Dublin, to add 200 jobs

Monday, May 11, 2015 03:19 PM

Alexion Pharmaceuticals will significantly expand its operations in Ireland by constructing the company's first ever biologics manufacturing facility outside the U.S. This $502.6 million, four-year project, which will be constructed at Alexion's College Park site in Blanchardstown, is expected to create approximately 200 additional full-time jobs on completion, bringing Alexion's total workforce in Ireland to almost 500.

More... »

UNC-Chapel Hill, GSK partner for HIV cure, launch Qura Therapeutics

Monday, May 11, 2015 02:06 PM

The University of North Carolina at Chapel Hill, a global public research university with experience in HIV basic and clinical research, and GlaxoSmithKline have created the dedicated HIV Cure Center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS. This unique public-private partnership will redefine the traditional way of conducting research and create a new model to seek the breakthroughs needed to tackle a global health issue.

More... »

Plasmatech Biopharmaceuticals to acquire Abeona Therapeutics

Friday, May 8, 2015 12:24 PM

PlasmaTech Biopharmaceuticals, a Texas-based biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, has entered into a definitive agreement to acquire Abeona Therapeutics, a company engaged in the development and commercialization of therapies for patients with lysosomal storage diseases. The company will issue to Abeona Therapeutic members a total of 3,979,761 common shares upon closing of the transaction, and up to an additional $9 million in performance milestones, in common stock or cash, at the company’s option.

More... »

Gilead Sciences acquires EpiTherapeutics

Thursday, May 7, 2015 12:24 PM

Gilead Sciences, headquartered in Foster City, Calif., has acquired EpiTherapeutics, a privately held Danish company, for $65 million, subject to certain purchase price adjustments, to be financed through available cash on hand.

More... »

Eli Lilly plans innovation center in Massachusetts

Thursday, May 7, 2015 12:22 PM

Eli Lilly plans to establish a new drug delivery and device innovation center in Cambridge, Mass.—a strategic location it says will help attract top scientists and bioengineers, as well as enhance Eli Lilly's local business development presence.

More... »

Alexion to acquire Synageva

Wednesday, May 6, 2015 02:56 PM

Cheshire, Conn.-based Alexion Pharmaceuticals will acquire Synageva, a biopharmaceutical company based in Lexington, Mass., for $115 in cash and 0.6581 Alexion shares for each share of Synageva, implying a total per share value of $230 based on the nine-day volume-weighted average closing price of Alexion stock through May 5.

More... »

CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs